Bagsværd, Denmark, 14 October 2022 – Novo Nordisk at the moment introduced that the acquisition of Forma Therapeutics Holdings, Inc. (Forma), introduced on 1 September 2022, has been accomplished.
Following the expiration of Novo Nordisk’s money tender supply for Forma, Novo Nordisk has at the moment acquired all excellent shares of frequent inventory of Forma at a worth of USD 20 per share in money, with out curiosity and fewer any relevant tax withholding.
Novo Nordisk has been suggested by the depositary for the tender supply {that a} complete of roughly 43,837,986 shares of Forma’s frequent inventory had been validly tendered and never validly withdrawn in the tender supply as of the tender supply expiration at one minute previous 11:59 pm EST 13 October 2022, which symbolize roughly 91.5% of the complete quantity of shares of Forma’s frequent inventory excellent.
Following the finalisation of the tender supply, Novo Nordisk accomplished the acquisition of Forma at the moment via a merger of Novo Nordisk’s wholly owned subsidiary with and into Forma wherein all shares not tendered into the supply had been cancelled and transformed into the proper to obtain money equal to the USD 20 supply worth per share, with out curiosity, much less any relevant tax withholding.
At the completion of the merger, Forma grew to become a completely owned subsidiary of Novo Nordisk. The frequent inventory of Forma will now not be listed or traded on the Nasdaq Global Select Market.
About the acquisition
For extra info, please see: Novo Nordisk to amass Forma Therapeutics and broaden presence in sickle cell illness and uncommon blood problems
About Novo Nordisk
Novo Nordisk is a number one world healthcare firm, based in 1923 and headquartered in Denmark. Our function is to drive change to defeat diabetes and different severe persistent illnesses similar to weight problems and uncommon blood and endocrine problems. We accomplish that by pioneering scientific breakthroughs, increasing entry to our medicines, and dealing to forestall and in the end treatment illness. Novo Nordisk employs about 50,800 folks in 80 international locations and markets its merchandise in round 170 international locations. For extra info, go to novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Further info
